Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EVALUATION OF COVID-19 VACCINATION EFFICACY AND CONTIXAGEVIMAB-CILGAVIMAB PROPHYLAXIS IN LIVER AND KIDNEY TRANSPLANT PATIENTS: PRELIMINARY STUDY

NCT05629923 is registered in ClinicalTrials.gov with University of Rome Tor Vergata as lead sponsor.

NCT NCT05629923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05629923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EVALUATION OF COVID-19 VACCINATION EFFICACY AND CONTIXAGEVIMAB-CILGAVIMAB PROPHYLAXIS IN LIVER AND KIDNEY TRANSPLANT PATIENTS: PRELIMINARY STUDY
Lead sponsor
University of Rome Tor Vergata
Phase
Observational
Overall status
Completed
Start date
February 1, 2022
Completion date
November 30, 2022
Enrollment
306 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pandemic, transplant-related disorder